We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
Product News

Expedeon AG Announces Commercial-Use Licence of Proprietary Technology in Diagnostic Assay

Rectangle Image
Product News

Expedeon AG Announces Commercial-Use Licence of Proprietary Technology in Diagnostic Assay

Credit: Expedeon
Expedeon AG announced the signing of a licence and supply agreement for its colloidal gold with South Korea-based PaxGenBio, a privately held, independent developer and supplier of rapid, highly sensitive multiplex diagnostic kits.

Expedeon’s colloidal gold is an aqueous suspension of spherical metallic nanoparticles manufactured to a high standard, demonstrating efficient antibody binding, for maximum sensitivity. PaxGenBio will deploy Expedeon’s gold nanoparticles in its MPCR-ULFA (multiplexed Polymerase Chain Reaction - universal lateral flow assays) technology. These assays will be used for the early, simultaneous detection of sexually transmitted diseases, including human papillomavirus, and tuberculosis. The term of the agreement is three years, with an option to extend.

Dr. Youngsuk Park, CEO of PaxGenBio, said: “We are very pleased to be working with Expedeon and its highly-skilled, experienced team. Following a thorough evaluation of colloidal gold from a number of manufacturers, we identified the Expedeon product as the most consistent and of highest quality.”

Dr. Heikki Lanckriet, CEO and CSO of Expedeon, commented: “Expedeon is committed to providing our customers with the highest level of service, quality and consistency. We are delighted that PaxGenBio has chosen to adopt our gold nanoparticles in the manufacturing of its diagnostic kits. Our commercially scalable, proprietary colloidal gold particle manufacturing and coating process provides particles of the highest quality and offers superior properties in terms of particle size and shape and their ability to conjugate antibodies or antigens.”
Advertisement